Cas:71138-71-1 Octapinol manufacturer & supplier

Chemical Name:Octapinol

CAS.NO:71138-71-1

Synonyms:4-(2-Propylpentyl)-1-piperidineethanol

Molecular Formula:C₁₅H₃₁NO

Molecular Weight:241.41300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:338.1ºC at 760 mmHg

Density:0.895g/cm3

Index of Refraction:1.465

PSA:23.47000

Exact Mass:241.24100

LogP:3.23510

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-(2-Propylpentyl)-1-piperidineethanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(2-Propylpentyl)-1-piperidineethanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(2-Propylpentyl)-1-piperidineethanol Use and application,4-(2-Propylpentyl)-1-piperidineethanol technical grade,usp/ep/jp grade.

Related News: From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity. Octapinol manufacturer The company��s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Octapinol supplier There are also new directives that relate to US citizens. Octapinol vendor There are also new directives that relate to US citizens. Octapinol factory From the perspective of the corresponding formulation manufacturer, the drug substance needs to meet the requirements of impurities and stability. The production base must pass the international quality system certifications such as cGMP and EuGMP. At the same time, the drug substance company must have sufficient capacity.